[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-neoplasms":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,78,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100616352","ai-for-renal-tumors-using-non-contrast-ct-100616352",false,"NCT07304492","AI for Renal Tumors Using Non-Contrast CT","An Artificial Intelligence Model for Screening and Diagnosis of Renal Tumors Based on Non-Contrast CT","Inclusion Criteria:\n\n1. Patients who underwent an abdominal CT examination.\n2. Patients with renal lesions were managed according to standard clinical pathways, which included follow-up, biopsy, or surgery.\n3. Malignant lesions were pathologically confirmed; benign lesions were confirmed by either pathological diagnosis or imaging follow-up.\n4. No prior treatment had been received for the renal disease.\n\nExclusion Criteria:\n\n1. Patients refuse to undergo recommended follow-up, biopsy, or surgery, which precluded definitive diagnosis of the renal lesion.\n2. Absence of complete pathological confirmation for lesions suspected to be malignant.\n3. Patients have received any form of prior treatment for the renal lesion.\n4. Poor image quality that hampered diagnostic evaluation.","ALL","18 Years","80 Years",{"count":20,"type":21},10000,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of this observational study is to learn whether the artificial intelligence method can automatically identify and diagnose renal lesions using non-contrast CT or opportunistic screening.",[26,27],"Renal Neoplasms","Renal Cyst",[29,26,27,30],"Artificial intelligence","Computer tomography","NOT_YET_RECRUITING","2025-12-13",{"date":34,"type":35},"2025-12-26","ACTUAL",{"date":37,"type":21},"2026-01",{"date":39,"type":21},"2028-12",{"name":41,"class":42},"Fudan University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":54,"studyType":23,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":43},"100598002","tumor-rupture-during-robotic-partial-nephrectomy-100598002","NCT07065825","Tumor Rupture During Robotic Partial Nephrectomy","A Retro-Prospective Observational Study on Causes, Characteristics, Intraoperative Management and Impact on Prognosis","RUPTURE","Inclusion Criteria:\n\n* Patients who experienced tumor rupture during RAPN (referred to an unintended breach of the tumor capsule with or without spillage of malignant tissue during tumor resection)\n* Patients who provide informed consent to participate\n* Patients from 18 to 80 years of age.\n\nExclusion Criteria:\n\n* Patients undergoing radical nephrectomy or other nephron-sparing procedures.\n* Patients undergoing partial nephrectomy with other approaches (open, pure laparoscopic)\n* Patients with multiple ipsilateral tumors\n* Patients diagnosed with genetic abnormalities that increase the likelihood of developing renal cell carcinoma.\n* Patients who deny consent.",{"count":53,"type":21},100,"5 Years","The RUPTURE Project is a multi-center observational study aiming to understand tumor rupture during robotic partial nephrectomy (RAPN), a minimally invasive surgery used to treat kidney tumors. Tumor rupture-an unintended break of the tumor capsule during surgery-occurs in about 10-15% of cases but is poorly studied. This event may increase the risk of cancer recurrence or spread, but its true impact is still unclear.\n\nThe study includes adult patients who experienced a tumor rupture during RAPN. Researchers will collect data on patient and tumor characteristics, surgical techniques, how the rupture occurred and was managed, and long-term outcomes. Follow-up visits will monitor for recurrence, metastases, and survival for up to five years. No experimental treatments or extra procedures are involved; only standard care is followed.\n\nBy analyzing at least 100 cases from various hospitals, the study hopes to clarify whether tumor rupture affects prognosis and to identify risk factors and best practices for managing it. This could help improve patient safety, surgical strategies, and future clinical guidelines. All data are handled confidentially, and participation is voluntary.",[57,26],"Kidney Cancer",[59,60,61,62,63,64,65,66,67,68],"robotic","robotic surgery","partial nephrectomy","tumor rupture","tumour rupture","tumor resection","kidney cancer","small renal mass","robotic partial nephrectomy","robot-assisted partial nephrectomy","2025-07-11",{"date":71,"type":35},"2025-07-15",{"date":73,"type":21},"2025-09",{"date":75,"type":21},"2030-12",{"name":77,"class":42},"Azienda Ospedaliera Universitaria Integrata Verona",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":54,"studyType":23,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":43},"100571028","optimising-renal-tumour-management-through-artificial-intelligence-modules-100571028","NCT06714916","Optimising Renal Tumour Management Through Artificial Intelligence Modules","Mutimodal Artificial Intelligence for Optimising Renal Tumour Management: Diagnosis, Surgery and Prognosis","Inclusion Criteria:\n\n* Patients with renal tumor which can be treated by surgery;\n* Complete CECT within 30 days before surgery;\n* Patients who fully understand this study and sign the informed consent;\n\nExclusion Criteria:\n\n* Patients with any item missing from the baseline clinical and pathological information;\n* Patients who has already metastasized by the time the tumor is discovered;\n* Previous treatment in any form, including surgery, targeted therapy and immunotherapy;",{"count":86,"type":21},2100,"The goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(AI). It will also measure the accuracy of the predictions from AI models. The main questions it aims to answer are:\n\n1. whether the AI module can accurately provide tumor-related information such as Benign or malignant, subtypes, grading, stage, etc. by learning from preoperative CT images.\n2. whether the AI module can help clinicians find out the most suitable surgical programme for people with renal tumor.\n3. whether the AI module can integrate CT images and pathology slides, offering supplementary prognostic information to improve postoperative survival.\n\nParticipants who complete a CT(usually Contrast-enhanced CT, CECT) examination and undergo radical or partial nephrectomy will carry out active surveillance and record postoperative survival data for 5 years.",[26,89,90],"Pathology","Renal Cell Cancer",[92,93,94,95,96,97],"Articicial Intelligence","Renal tumors","Prediction Model","Surgery","Radiomics","Pathomics","RECRUITING","2025-03-16",{"date":101,"type":35},"2025-03-19",{"date":103,"type":35},"2025-01-01",{"date":105,"type":21},"2033-12-31",{"name":107,"class":42},"Shao Pengfei",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100261893","a-cpg-methylation-based-assay-for-stratifying-stage-iii-clear-cell-renal-cell-carcinoma-of-receiving-adjuvant-treatment-100261893","NCT02688491","A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment","A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Adjuvant Targeted Therapy of Stage III Clear Cell Renal Cell Carcinoma Based on a CpG-methylation-based Assay","Inclusion Criteria:\n\n* The informed consent has been obtained from the patient.\n* With confirmed diagnosis of stage III clear cell renal cell carcinoma\n* With moderate\u002Fgood ECOG health rating (PS): 0-1 score.\n* The patient receive no anti-cancer treatment before primary surgery.\n* The patient receive radical operation for renal cancer with negative margin.\n\nExclusion Criteria:\n\n* With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.\n* With bad compliance or contraindication to enrollment.\n* Pregnant woman or lactating woman.\n* With contraindication to receive adjuvant targeted therapy.","75 Years",{"count":117,"type":21},300,"INTERVENTIONAL",[120],"NA","Whether patients with stage III clear cell renal cell carcinoma(ccRCC) should receive adjuvant targeted therapy or not is still on debate. The investigators invented a assay consisting of 5 CpGs: cg00396667（PITX1）, cg18815943 （FOXE3）, cg03890877（TWF2）, cg07611000 （EHBP1L1）and cg14391855（RIN1）that was successfully categorise patients with stage III clear cell renal cell carcinoma into high-risk and low-risk groups with Harzard Ratio(HR) of 4.93. Here the investigators randomly assign assay-defined high risk patients of locally advanced ccRCC into adjuvant targeted therapy group and observation group.Disease free survival and overall survival are the end points of observation.",[26,123],"Targeted Molecular Therapy","2016-02-24",{"date":126,"type":21},"2016-02-25",{"date":128,"type":4},"2016-07",{"date":130,"type":21},"2026-07",{"name":132,"class":42},"First Affiliated Hospital, Sun Yat-Sen University"]